Stock Analysis
Bio-Rad Laboratories, Inc.Class ABIO
P/E 42.52×· 5Y range 2.38–50.82×· 70th percentile of history
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsBuy10 analystsP/E 42.5× sits at the 70th percentile of its 5.065023956194388-year history.
Cash covers 128% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Financial Health85
- Quality60
Risks
- Growth20
- Profitability28
Mixed picture — no clear quality or value edge.
Market context
-3.0% today· Z 1.4σ
Bull Case
- ✓Altman Z 3.5 — safe-zone balance sheet
What's happening with BIO
Profile
Strong financial health; growth, profitability, valuation and moat lag behind.
How is each axis scored?
- Valuation37/100 · Weak
- P/E vs own history (70th pct)5/25
- FCF yield (3.7%)12/25
- P/S (3.7x)20/25
- EV/EBIT (171.1x)0/25
- Growth20/100 · Weak
- Revenue CAGR (-3.0%)0/25
- Net income CAGR (-35.0%)0/25
- EPS CAGR 5Y (-33.3%)0/25
- Fwd implied growth (17.2%)20/25
- Profitability28/100 · Weak
- ROIC (0.6%)5/25
- ROE (3.0%)5/25
- Net margin (8.6%)13/25
- Operating margin (2.1%)5/25
- Financial Health85/100 · Strong
- Altman Z (3.47)25/25
- Current ratio (5.62)25/25
- Interest coverage (4.4x)10/25
- Net cash / debt (Net cash)25/25
- Quality60/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.35)20/25
- FCF conversion (n/a)0/25
- Margin stability (σ 4.2%)25/25
- Moat38/100 · Weak
- ROIC >12% years (0/8 yrs)0/25
- Median gross margin (54.1%)20/25
- FCF-positive years (9/10 yrs)18/25
- Worst-year net margin (worst -129.4%)0/25
Risk Flags
- ⚠3 loss-making years in recent history
- ⚠Revenue shrinking 3.0%/yr
About Bio-Rad Laboratories, Inc.Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. Show more
In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Headquarters: HERCULES, CA · Employees: 7,450 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
37DP/E (TTM)42.5xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 2.4x–50.8x · 70th pct
P/FCF27.6xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.7%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.0%–5.9% · 71st pct
P/S (TTM)3.65xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 2.4x–8.4x · 48th pct
EV/EBIT171.1xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 1.5x–176.7x · highest in history
EV/Sales4.0xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E36.3xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.27xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
28EROIC0.6%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE3.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA2.2%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin8.6%C
Grade C: AverageNet Income / Revenue
Operating Margin2.1%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin51.9%A
Grade A: PremiumGross Profit / Revenue
FCF Margin13.6%C
Grade C: AverageFCF / Revenue
True FCF Margin13.6%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
20ERevenue CAGR-3.0%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-35.0%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-33.3%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth17.2%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-11.4%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
85AAltman Z-Score3.47A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.62xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.18xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.4xC
Grade C: OkEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.16xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.28xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
60BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.35A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability4.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue5.4%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.26xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 records| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
ENGELHARDT EVA ANETTE Filed | ENGELHARDT EVA ANETTE | SellOpen market sale | -550 | |
ENLOE COURTNEY C Filed | ENLOE COURTNEY C | Option exercise | -186 | |
ENLOE COURTNEY C Filed | ENLOE COURTNEY C | Tax withholding | -77 | |
ENLOE COURTNEY C Filed | ENLOE COURTNEY C | Option exercise | +186 | |
Lakkaraju Roop Kalyan Filed | Lakkaraju Roop Kalyan | Option exercise | -1078 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Lakkaraju Roop Kalyan Filed | Lakkaraju Roop Kalyan | Tax withholding | -420 | |
Lakkaraju Roop Kalyan Filed | Lakkaraju Roop Kalyan | Option exercise | +1.1K | |
PEI MELINDA LITHERLAND Filed | PEI MELINDA LITHERLAND | Option exercise | -407 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
38DROIC >12% Years0/8 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)54.1%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years9/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-129.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$8.32
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$60.53
Cash & short-term investments per share (Finnhub)
Book Value / Share$268.30
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.20B
Total debt obligations (short + long term)
Cash & Equiv.$1.54B
Cash and short-term investments
Net Debt$-339.00MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$7.45B
Shareholders' equity (book value)
Asset / Liability3.39xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$9.46B
Current Market Capitalization
Beta1.07B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Bio-Rad Laboratories, Inc.Class A (BIO)
BIO is down 3.05% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Bio-Rad Laboratories, Inc.Class A. Altman Z-Score of 3.47 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.35 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -3%), which weighs on the growth outlook.
- Company is effectively debt-free after netting cash.
- Bio-Rad Laboratories, Inc.Class A posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
See how BIO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BIO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 6 | After-hours | 358.97 | -5.49% | -2.72 |
| Oct 2 | Regular | 368.69 | +3.69% | 2.32 |
| Oct 2 | After-hours | 369.14 | +3.82% | 2.39 |
| Oct 1 | Regular | 358.17 | -5.17% | -4.30 |
| Sep 24 | Regular | 388.48 | +2.53% | 2.31 |
Frequently Asked Questions about BIO
What is the current Bio-Rad Laboratories, Inc.Class A (BIO) stock price?
BIO is trading at $353.70 at the last market close, down 3.05% on the session. PreMarketPrice tracks BIO pre-market, intraday and after-hours prices.
Is BIO stock a buy right now?
PreMarketPrice's quantitative model rates Bio-Rad Laboratories, Inc.Class A's financial health at 85/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BIO stock overvalued?
Bio-Rad Laboratories, Inc.Class A trades at a trailing P/E of 42.5 and our valuation score rates it 37/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bio-Rad Laboratories, Inc.Class A report earnings?
No confirmed earnings date is currently scheduled for BIO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bio-Rad Laboratories, Inc.Class A operate in?
Bio-Rad Laboratories, Inc.Class A operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Bio-Rad Laboratories, Inc.Class A do?
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets.
About Bio-Rad Laboratories, Inc.Class A (BIO) Stock
Bio-Rad Laboratories, Inc.Class A (BIO) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, Bio-Rad Laboratories, Inc.Class A is trading at $353.70, down 3.05% on the day with a market capitalization of $9.5 billion. The financial health score for BIO is 85/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BIO stock.
BIO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bio-Rad Laboratories, Inc.Class A (BIO) across multiple dimensions:
- Pre-market price & movement: Real-time BIO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BIO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bio-Rad Laboratories, Inc.Class A across multiple reporting periods.
- Financial health score: A composite score of 85/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BIO.
- Sector peers: Compare BIO against 6 other technology stocks on key financial metrics.
Is BIO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bio-Rad Laboratories, Inc.Class A (BIO) as an investment. The financial health score of 85/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bio-Rad Laboratories, Inc.Class A (BIO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.